Compare MQ & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MQ | MLYS |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.2B |
| IPO Year | 2021 | 2023 |
| Metric | MQ | MLYS |
|---|---|---|
| Price | $4.34 | $29.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $5.36 | ★ $48.67 |
| AVG Volume (30 Days) | ★ 2.7M | 1.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $624,884,000.00 | N/A |
| Revenue This Year | $16.89 | N/A |
| Revenue Next Year | $16.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.25 | N/A |
| 52 Week Low | $3.70 | $12.59 |
| 52 Week High | $7.04 | $47.65 |
| Indicator | MQ | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 57.16 |
| Support Level | $3.84 | $26.85 |
| Resistance Level | $4.50 | $31.19 |
| Average True Range (ATR) | 0.13 | 1.65 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 62.38 | 64.08 |
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.